[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].

about

[Serum CYFRA21-1 is Correlated with the Efficacy of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients Harboring EGFR Mutations].

Item

http://www.wikidata.org/entity/Q54177645

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@en

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@nl

type

Item

label

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@en

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@nl

prefLabel

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@en

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@nl

P1476

[Serum CYFRA21-1 is Correlated ...... nts Harboring EGFR Mutations].

@en

P2093

Aimin Hu

http://www.w3.org/2001/XMLSchema#string

Baohua Lu

http://www.w3.org/2001/XMLSchema#string

Baolan Li

http://www.w3.org/2001/XMLSchema#string

Fanbin Hu

http://www.w3.org/2001/XMLSchema#string

Hongmei Zhang

http://www.w3.org/2001/XMLSchema#string

Hua Zheng

http://www.w3.org/2001/XMLSchema#string

Jie Li

http://www.w3.org/2001/XMLSchema#string

Qunhui Wang

http://www.w3.org/2001/XMLSchema#string

Tongmei Zhang

http://www.w3.org/2001/XMLSchema#string

Ying Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.

P304

550-558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3779/J.ISSN.1009-3419.2016.08.12

http://www.w3.org/2001/XMLSchema#string

P407

Chinese

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27561807

http://www.w3.org/2001/XMLSchema#string

P932

5972987

http://www.w3.org/2001/XMLSchema#string